Company research
Jasper Therapeutics, Inc.
CIK 1788028Updated Nov 10, 2026
SecurityJSPR · NASDAQ · equity
Name history
Amplitude Healthcare Acquisition Corp · through Sep 29, 2021
JSPR price & chart
Loading TradingView…
NASDAQ:JSPR on TradingView ↗About the company
Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The company is advancing a pipeline of medicines including vensobafusp alfa, briquilimab, and KP701. Vensobafusp alfa is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant in severe combined immunodeficiencies (SCID), Fanconi anemia, as well as mast cell mediated diseases such as the chronic urticarias. KP701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.
In the news
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value ↗
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. Nov 14, 2025, 23:46 ET Share this article Share to X Share this article Share to X NEW YORK , Nov. 14, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a glo ↗
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm News provided by The Schall Law Firm Nov 14, 2025, 03:10 ET Share this article Share to X Share this article Share to X LOS ANGELES , Nov. 14, 2025 /PRNewswire/ -- The Schall Law Firm ↗
Recent filings
Other Events
Items 8.01, 9.01
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 3.03, 5.03, 7.01, 9.01
SCHEDULE 13G - filed by BANK OF AMERICA CORP /DE/ regarding Jasper Therapeutics, Inc.
SC TO-I/A - filed by Jasper Therapeutics, Inc. regarding Jasper Therapeutics, Inc.
DEF 14A filing
Show 5 more recent filings
Other Events
Items 8.01, 9.01
S-3 filing
PRE 14A filing
Other Events
Items 8.01, 9.01
SC TO-I - filed by Jasper Therapeutics, Inc. regarding Jasper Therapeutics, Inc.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 57,469,000Source | 99,413,000Source | 11,802,000Source | 46,466,000Source | 113,929,000Source | 21,184,000Source | 57,597,000Source | 125,963,000Source | 35,779,000Source | 79,899,000Source | 94,892,000Source | 48,361,000Source |
| Property, Plant and Equipment, NetUSD | 1,102,000Source | 2,071,000Source | 60,000Source | 1,331,000Source | 2,438,000Source | 81,000Source | 1,599,000Source | 2,464,000Source | 102,000Source | 1,875,000Source | 2,727,000Source | 3,568,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 50,899,000Source | 92,502,000Source | 7,314,000Source | 39,510,000Source | 106,819,000Source | 14,144,000Source | 48,799,000Source | 118,475,000Source | 28,692,000Source | 71,637,000Source | 86,887,000Source | 38,250,000Source |
| Assets, CurrentUSD | 54,564,000Source | 94,806,000Source | 11,571,000Source | 42,966,000Source | 108,680,000Source | 20,292,000Source | 53,174,000Source | 120,308,000Source | 34,645,000Source | 75,811,000Source | 88,938,000Source | 41,731,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,665,000Source | 2,304,000Source | 3,840,000Source | 3,456,000Source | 1,861,000Source | 6,148,000Source | 4,375,000Source | 1,833,000Source | 5,953,000Source | 4,174,000Source | 2,051,000Source | 2,818,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,236,000Source | 1,106,000Source | 128,000Source | 1,560,000Source | 1,231,000Source | 317,000Source | 1,875,000Source | 1,351,000Source | 502,000Source | 976,000Source | 1,467,000Source | 1,886,000Source |
| Other Assets, NoncurrentUSD | 150,000Source | 1,013,000Source | 43,000Source | 192,000Source | 1,163,000Source | 77,000Source | 532,000Source | 1,423,000Source | 113,000Source | 820,000Source | 1,343,000Source | 759,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 45,898,000Source | 15,733,000Source | 10,389,000Source | 22,965,000Source | 13,619,000Source | 17,784,000Source | 15,353,000Source | 12,733,000Source | 31,628,000Source | 18,225,000Source | 16,452,000Source | 12,372,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,000Source | 2,000Source | 3,000Source | 2,000Source | 2,000Source | 3,000Source | 2,000Source | 2,000Source | 3,000Source | 2,000Source | 1,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 319,137,000Source | 300,226,000Source | 322,014,000Source | 312,332,000Source | 298,219,000Source | 321,241,000Source | 304,352,000Source | 296,556,000Source | 320,818,000Source | 302,541,000Source | 248,039,000Source | 141,120,000Source |
| Retained Earnings (Accumulated Deficit)USD | -307,569,000Source | -216,548,000Source | -320,604,000Source | -288,833,000Source | -197,911,000Source | -317,844,000Source | -262,110,000Source | -183,328,000Source | -316,670,000Source | -240,869,000Source | -169,600,000Source | -105,135,000Source |
| Stockholders' Equity Attributable to ParentUSD | 11,571,000Source | 83,680,000Source | 1,413,000Source | 23,501,000Source | 100,310,000Source | 3,400,000Source | 42,244,000Source | 113,230,000Source | 4,151,000Source | 61,674,000Source | 78,440,000Source | 35,989,000Source |
| Liabilities and EquityUSD | 57,469,000Source | 99,413,000Source | 11,802,000Source | 46,466,000Source | 113,929,000Source | 21,184,000Source | 57,597,000Source | 125,963,000Source | 35,779,000Source | 79,899,000Source | 94,892,000Source | 48,361,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 21,041,000Source | 12,459,000Source | 7,845,000Source | 20,500,000Source | 10,068,000Source | 8,996,000Source | 12,334,000Source | 8,916,000Source | 13,200,000Source | 15,237,000Source | 12,374,000Source | 7,065,000Source |
| Operating Lease, Liability, CurrentUSD | 1,703,000Source | 1,059,000Source | 270,000Source | 1,954,000Source | 1,029,000Source | 757,000Source | 1,835,000Source | 1,000,000Source | 1,235,000Source | 1,089,000Source | 972,000Source | 865,000Source |
| Accounts Payable, CurrentUSD | 9,166,000Source | 3,086,000Source | 2,778,000Source | 8,034,000Source | 2,964,000Source | 2,439,000Source | 2,995,000Source | 2,391,000Source | 6,220,000Source | 4,027,000Source | 4,149,000Source | 1,768,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 1,010,000Source | — | 201,000Source | 1,287,000Source | — | 755,000Source | 1,553,000Source | — | 724,000Source | 1,814,000Source | 2,786,000Source |
| Other Liabilities, NoncurrentUSD | 2,264,000Source | 2,264,000Source | — | 2,264,000Source | 2,264,000Source | 2,264,000Source | 2,264,000Source | 2,264,000Source | 2,264,000Source | 2,264,000Source | 2,264,000Source | 2,353,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | — | 37,700,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 21,000Source | 279,000Source | 1,056,000Source | 1,373,000Source | 1,108,000Source | 1,000,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 423,000Source | 1,811,000Source | 6,713,000Source | 6,619,000Source | 5,211,000Source | 4,091,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -3,781,000Source | -1,039,000Source | 2,193,000Source | -122,000Source | 2,381,000Source | -2,151,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -14,548,000Source | -22,842,000Source | -77,161,000Source | -62,602,000Source | -52,067,000Source | -45,858,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | 4,000Source | 5,000Source | -532,000Source | -267,000Source | -576,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | — | 960,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 34,211,000Source | 47,884,000Source | 100,971,000Source | 55,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 51,316,000Source | 92,919,000Source | 7,731,000Source | 39,927,000Source | 14,561,000Source | 49,216,000Source | 29,109,000Source | 72,054,000Source | 87,304,000Source | 38,667,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,424,000Source | 1,998,000Source | — | — | — | 1,811,000Source | — | 6,619,000Source | — | — |
| Deferred Other Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 327,000Source | — | — |
| Equipment ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 1,706,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | -11,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 4,775,000Source | 5,434,000Source | 4,072,000Source | 5,880,000Source | 5,138,000Source | 5,645,000Source | 20,779,000Source | 20,418,000Source | 17,076,000Source | 16,569,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 2,000Source | — | — |
| Investment Income, InterestUSD | — | — | 342,000Source | 1,284,000Source | 82,000Source | 437,000Source | 164,000Source | 624,000Source | 1,741,000Source | 5,058,000Source | 5,199,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,736,000Source | -18,637,000Source | -2,760,000Source | -26,723,000Source | -1,174,000Source | -21,241,000Source | -75,801,000Source | -71,269,000Source | -64,465,000Source | -37,685,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | -26,723,000Source | — | -21,241,000Source | — | -71,269,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 430,000Source | 1,252,000Source | 6,447,000Source | 353,000Source | 9,778,000Source | 561,000Source | 8,082,000Source | 4,970,000Source | — | — |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 1,200,000Source |
| Operating ExpensesUSD | — | — | 19,166,000Source | 19,889,000Source | 9,207,000Source | 27,076,000Source | 10,952,000Source | 21,802,000Source | 83,883,000Source | 76,239,000Source | 68,861,000Source | 51,196,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | 400,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | — | — | -2,011,000Source | -32,000Source | 2,385,000Source | -84,000Source | -26,000Source | -63,000Source | -2,187,000Source | -88,000Source | — | 586,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 6,500,000Source | — | 6,454,000Source | 47,195,000Source | — | 28,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | 329,000Source | 388,000Source | 27,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | 2,253,000Source | — | — | — |
| Depreciation | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — |
| Operating Income (Loss)USD | — | — | -19,166,000Source | -19,889,000Source | -9,207,000Source | -27,076,000Source | -10,952,000Source | -21,802,000Source | -83,883,000Source | -76,239,000Source | -68,861,000Source | -51,196,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -2,011,000Source | -32,000Source | 2,385,000Source | -84,000Source | -26,000Source | -63,000Source | -2,187,000Source | -88,000Source | — | 586,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 2,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,736,000Source | -18,637,000Source | -2,760,000Source | -26,723,000Source | -1,174,000Source | -21,241,000Source | -75,801,000Source | -71,269,000Source | -64,465,000Source | -37,685,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.13Source | -1.24Source | -0.1Source | -1.74Source | -0.04Source | -1.41Source | -3.95Source | -4.89Source | -6.18Source | -1.03Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.13Source | -1.24Source | -0.1Source | -1.74Source | -0.04Source | -1.41Source | -3.95Source | -4.89Source | -6.18Source | -1.03Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 16,635,784Source | 15,000,516Source | 28,696,937Source | 15,333,962Source | 28,671,819Source | 15,022,122Source | 19,168,110Source | 14,584,870Source | 10,439,034Source | 36,482,761Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 16,635,784Source | 15,000,516Source | 28,696,937Source | 15,333,962Source | 28,671,819Source | 15,022,122Source | 19,168,110Source | 14,584,870Source | 10,439,034Source | 36,482,761Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 21,000Source | 279,000Source | 1,056,000Source | 1,373,000Source | — | 975,000Source |
| Equipment ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 1,706,000Source |
| General and Administrative ExpenseUSD | — | — | 4,775,000Source | 5,434,000Source | 4,072,000Source | 5,880,000Source | 5,138,000Source | 5,645,000Source | 20,779,000Source | 20,418,000Source | 17,076,000Source | 16,569,000Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | -246,000Source | — |
| Investment Income, InterestUSD | — | — | 342,000Source | 1,284,000Source | 82,000Source | 437,000Source | 164,000Source | 624,000Source | 1,741,000Source | 5,058,000Source | 5,199,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | -26,723,000Source | — | -21,241,000Source | — | -71,269,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 430,000Source | 1,252,000Source | 6,447,000Source | 353,000Source | 9,778,000Source | 561,000Source | 8,082,000Source | 4,970,000Source | — | — |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 1,200,000Source |
| Operating ExpensesUSD | — | — | 19,166,000Source | 19,889,000Source | 9,207,000Source | 27,076,000Source | 10,952,000Source | 21,802,000Source | 83,883,000Source | 76,239,000Source | 68,861,000Source | 51,196,000Source |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | 4,396,000Source | 13,511,000Source |
| Research and Development ExpenseUSD | — | — | 14,391,000Source | 14,455,000Source | 5,135,000Source | 21,196,000Source | 5,814,000Source | 16,157,000Source | 63,104,000Source | 55,821,000Source | 51,785,000Source | 34,627,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | 2,253,000Source | — | — | — |
Offerings
Registration 333-299459
Filing attachments
ea031143301ex99-1.htm · 8-K · 2026-11-09
Exhibit 99.1 JASPER THERAPEUTICS, INC. ANNOUNCES RESULTS OF THE THE OFFER TO PURCHASE RELATING TO ITS WARRANTS REDWOOD CITY, Calif., November 9, 2026 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the results of its offer to purchase (the “Offer”) all of its outstanding warrants to purchase shares of i…
Read attachment ↗ea030997801ex99-1.htm · 8-K · 2026-11-04
Exhibit 99.1 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split REDWOOD CITY, Calif., November 4, 2026 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced a 1-for-30 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock”) that will become effective at 12:01 a.m. Eastern T…
Read attachment ↗ea030865701ex99-1.htm · 8-K · 2026-10-15
Exhibit 99.1 Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy Initial Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026 Announces expansion cohort in patients with FSGS, with first patients anticipated to be dosed in first quarter 2027 REDWOOD CITY, Calif., October 15, 2026 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), …
Read attachment ↗ea030792501ex99-1.htm · 8-K · 2026-10-07
Exhibit 99.1 Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants REDWOOD CITY, Calif., October 7, 2026 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the “Offer”) any and all of its outstanding warrants to purchase shares of …
Read attachment ↗ea030686001ex99-1.htm · 8-K/A · 2026-10-01
Exhibit 99.1 KIRA PHARMACEUTICALS INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS Independent Auditors’ Report F-2 Consolidated Balance Sheets F-4 Consolidated Statements of Operations and Comprehensive Loss F-5 Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit F-6 Co…
Read attachment ↗ea030686001ex99-2.htm · 8-K/A · 2026-10-01
Exhibit 99.2 KIRA PHARMACEUTICALS INDEX TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets F-2 Condensed Consolidated Statements of Operations and Comprehensive Loss F-3 Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Deficit F-4 Condensed Consolidated Statements of Cash Flows …
Read attachment ↗